Skip to main content

Animations

MJFF Publications

5411 - 5420 of 8808 Results
Title
Year
  • Year
  • 2023
  • 2019
  • 2005
  • 2015
  • 2022
  • 2018
  • 2022
  • 2021
  • 2023
  • 2017
  • Summary Details
    OPEN
    Title: Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(23)00109-6
    Citation Count: 465
  • Summary Details
    RESTRICTED
    Title: What’s the target: understanding two decades of in silico microRNA-target prediction
    Journal Name: Briefings in Bioinformatics
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1093/bib/bbz111
    Citation Count: 51
  • Summary Details
    RESTRICTED
    Title: Oxidative Damage in Parkinson's Disease
    Journal Name: Antioxidants & Redox Signaling
    Publisher: Mary Ann Liebert Inc
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1089/ars.2005.7.627
    Citation Count: 27
  • Summary Details
    OPEN
    Title: Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson’s Disease 1
    Journal Name: Journal of Parkinson's Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: unspecified-oa
    DOI - Digital Object Identifier: 10.3233/jpd-150570
    Citation Count: 29
  • Summary Details
    OPEN
    Title: Quantifying regional α ‐synuclein, amyloid β, and tau accumulation in lewy body dementia
    Journal Name: Annals of Clinical and Translational Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/acn3.51482
    Citation Count: 35
  • Summary Details
    OPEN
    Title: Quantitative Analysis of the Brain Ubiquitylome in Alzheimer's Disease
    Journal Name: PROTEOMICS
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/pmic.201800108
    Citation Count: 66
  • Summary Details
    OPEN
    Title: Tumor suppressor PALB2 maintains redox and mitochondrial homeostasis in the brain and cooperates with ATG7/autophagy to suppress neurodegeneration
    Journal Name: PLOS Genetics
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1371/journal.pgen.1010138
    Citation Count: 8
  • Summary Details
    OPEN
    Title: PathoFact: a pipeline for the prediction of virulence factors and antimicrobial resistance genes in metagenomic data
    Journal Name: Microbiome
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s40168-020-00993-9
    Citation Count: 145
  • Summary Details
    OPEN
    Title: Antipsychotic drug efficacy correlates with the modulation of D1 rather than D2 receptor-expressing striatal projection neurons
    Journal Name: Nature Neuroscience
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s41593-023-01390-9
    Citation Count: 50
  • Summary Details
    RESTRICTED
    Title: Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double‐blind, placebo‐controlled multicenter study
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.27092
    Citation Count: 13
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.